FY2026 EPS Estimates for Soligenix Lowered by Zacks Research

Soligenix Inc. (NASDAQ:SNGX) – Equities research analysts at Zacks Research reduced their FY2026 earnings per share estimates for shares of Soligenix in a report issued on Monday, April 6th. Zacks Research analyst D. Bautz now expects that the biopharmaceutical company will post earnings of ($1.14) per share for the year, down from their prior estimate of ($0.78). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Research also issued estimates for Soligenix’s FY2027 earnings at ($0.83) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Soligenix Stock Performance

Shares of Soligenix stock opened at $1.14 on Wednesday. The stock has a market cap of $11.75 million, a price-to-earnings ratio of -0.32 and a beta of 1.93. The stock has a 50 day moving average price of $1.17 and a 200-day moving average price of $1.36. Soligenix has a one year low of $1.00 and a one year high of $6.23.

Institutional Investors Weigh In On Soligenix

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Soligenix during the 4th quarter valued at $37,000. StoneX Group Inc. bought a new stake in Soligenix during the 4th quarter valued at $50,000. Jane Street Group LLC bought a new stake in Soligenix during the 4th quarter valued at $51,000. Banco BTG Pactual S.A. bought a new stake in Soligenix during the 3rd quarter valued at $54,000. Finally, Virtu Financial LLC bought a new stake in Soligenix during the 3rd quarter valued at $59,000. 3.60% of the stock is owned by institutional investors.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.